BR112012024576A2 - composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição - Google Patents

composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição

Info

Publication number
BR112012024576A2
BR112012024576A2 BR112012024576A BR112012024576A BR112012024576A2 BR 112012024576 A2 BR112012024576 A2 BR 112012024576A2 BR 112012024576 A BR112012024576 A BR 112012024576A BR 112012024576 A BR112012024576 A BR 112012024576A BR 112012024576 A2 BR112012024576 A2 BR 112012024576A2
Authority
BR
Brazil
Prior art keywords
salts
modified release
desvenlafaxine
composition
preparing
Prior art date
Application number
BR112012024576A
Other languages
English (en)
Inventor
Girish Kumar Jain
Premchand Dalichandji Nakhat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of BR112012024576A2 publication Critical patent/BR112012024576A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

forma de dosagem de liberação modificada compreendendo desvenlafaxina ou sais da mesma. a presente invenção refere-se as composições faramacêuticas de liberação modificada compreendendo desvenilafaxina ou sais da mesma, um sistema modificador da taxa de liberação que controla a liberação de agente ativo em ambos os ambientes acídio e básico para fornecer liberação prolongada de ingrediente ativo , e opcionalmente um ou mais outro excipiente farmaceuticamente aceitável. a presente in venção tambpem se refere ao processo para preparação de tais composições e o método de usar tais composições. as composições farmacêuticas da presente invenão são úteis no provimento de níveis terapeuticamente eficazes de agente ativo durante período de tempo prolongado.
BR112012024576A 2010-03-31 2011-03-21 composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição BR112012024576A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1099MU2010 2010-03-31
PCT/IB2011/051160 WO2011121475A2 (en) 2010-03-31 2011-03-21 Modified release dosage form comprising desvenlafaxine or salts thereof

Publications (1)

Publication Number Publication Date
BR112012024576A2 true BR112012024576A2 (pt) 2016-05-31

Family

ID=44511833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024576A BR112012024576A2 (pt) 2010-03-31 2011-03-21 composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição

Country Status (6)

Country Link
US (1) US9408814B2 (pt)
EP (1) EP2552419A2 (pt)
BR (1) BR112012024576A2 (pt)
CA (1) CA2792352C (pt)
MX (1) MX2012010659A (pt)
WO (1) WO2011121475A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9230069B2 (en) 2013-04-16 2016-01-05 International Business Machines Corporation Execution-based license discovery and optimization

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
ES2290281T5 (es) 2001-02-12 2017-09-11 Wyeth Llc Sal de succinato de O-desmetil-venlafaxina
US20050244498A1 (en) 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
NZ537142A (en) 2002-06-10 2008-01-31 Wyeth Corp Novel formate salt of O-desmethyl-venlafaxine
JP2007520553A (ja) 2004-02-06 2007-07-26 ワイス 多微粒子ｏ−デスメチルベンラファキシン塩およびその使用
WO2006094083A1 (en) 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
JP2008534592A (ja) 2005-03-31 2008-08-28 ワイス Ｏ−デスメチルベンラファキシンおよびバゼドキシフェンの組み合わせ生成物およびその使用
WO2007011619A2 (en) 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
SG172660A1 (en) * 2006-06-01 2011-07-28 Schering Corp Pharmaceutical compositions for sustained release of phenylephrine
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
US7820716B2 (en) 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
US20100330172A1 (en) 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
AU2007362336A1 (en) 2007-12-10 2009-06-18 Wyeth Llc O-desmethyl-venlafaxine for treating major depressive disorder
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
EP2119696A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
US20100209489A1 (en) 2009-02-04 2010-08-19 Supernus Pharmaceuticals, Inc. Formulations of desvenlafaxine

Also Published As

Publication number Publication date
MX2012010659A (es) 2013-03-05
CA2792352A1 (en) 2011-10-06
WO2011121475A2 (en) 2011-10-06
EP2552419A2 (en) 2013-02-06
CA2792352C (en) 2015-06-23
US20130059917A1 (en) 2013-03-07
US9408814B2 (en) 2016-08-09
WO2011121475A3 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015031878A2 (pt) composição farmacêutica
BR112018012870A2 (pt) métodos e composições para o tratamento de transtornos relacionados à crise
PE20140255A1 (es) Tableta dispersable en forma oral
BR112015011430A2 (pt) composição para liberação imediata e prolongada
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
BR112014016450A2 (pt) composto antagonista de leucotrieno b4

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)